Cargando…

Adverse Reactions after Administration of Antivenom in Korea

Kovax(®) antivenom is the main treatment for toxins produced by the Gloydius species. However, research on adverse reactions after Kovax(®) antivenom administration is scarce. We aimed to identify the incidence and characteristics of adverse reactions after Kovax(®) antivenom administration. We cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Jin Seok, Kang, Hyunggoo, Cho, Yongil, Shin, Hyungoo, Lee, Heekyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472312/
https://www.ncbi.nlm.nih.gov/pubmed/32781766
http://dx.doi.org/10.3390/toxins12080507
_version_ 1783578959899787264
author Shim, Jin Seok
Kang, Hyunggoo
Cho, Yongil
Shin, Hyungoo
Lee, Heekyung
author_facet Shim, Jin Seok
Kang, Hyunggoo
Cho, Yongil
Shin, Hyungoo
Lee, Heekyung
author_sort Shim, Jin Seok
collection PubMed
description Kovax(®) antivenom is the main treatment for toxins produced by the Gloydius species. However, research on adverse reactions after Kovax(®) antivenom administration is scarce. We aimed to identify the incidence and characteristics of adverse reactions after Kovax(®) antivenom administration. We conducted a retrospective review of the medical records of snakebite patients in Korea between January 2008 and September 2019. We identified the frequency, characteristics, and treatments of adverse reactions to Kovax(®) antivenom. There were 150 patients with snakebites, of whom 121 (80.7%) patients received Kovax(®) antivenom. Adverse reactions occurred in five patients (4.1%). Acute adverse reactions within 24 h of antivenom administration occurred in two patients (1.7%). The symptoms of patients with acute adverse reactions were nausea, diaphoresis, dizziness, and hypotension. Delayed adverse reactions that occurred 24 h after antivenom administration were reported in three patients (2.5%). One patient had a skin rash after 10 days, and two patients had fever 37 and 48 h after antivenom use. In conclusion, most patients were managed safely after Kovax(®) antivenom, and the incidence of adverse reactions was low. Severe adverse reactions occurred in a small percentage of patients, and there were no deaths.
format Online
Article
Text
id pubmed-7472312
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74723122020-09-04 Adverse Reactions after Administration of Antivenom in Korea Shim, Jin Seok Kang, Hyunggoo Cho, Yongil Shin, Hyungoo Lee, Heekyung Toxins (Basel) Article Kovax(®) antivenom is the main treatment for toxins produced by the Gloydius species. However, research on adverse reactions after Kovax(®) antivenom administration is scarce. We aimed to identify the incidence and characteristics of adverse reactions after Kovax(®) antivenom administration. We conducted a retrospective review of the medical records of snakebite patients in Korea between January 2008 and September 2019. We identified the frequency, characteristics, and treatments of adverse reactions to Kovax(®) antivenom. There were 150 patients with snakebites, of whom 121 (80.7%) patients received Kovax(®) antivenom. Adverse reactions occurred in five patients (4.1%). Acute adverse reactions within 24 h of antivenom administration occurred in two patients (1.7%). The symptoms of patients with acute adverse reactions were nausea, diaphoresis, dizziness, and hypotension. Delayed adverse reactions that occurred 24 h after antivenom administration were reported in three patients (2.5%). One patient had a skin rash after 10 days, and two patients had fever 37 and 48 h after antivenom use. In conclusion, most patients were managed safely after Kovax(®) antivenom, and the incidence of adverse reactions was low. Severe adverse reactions occurred in a small percentage of patients, and there were no deaths. MDPI 2020-08-06 /pmc/articles/PMC7472312/ /pubmed/32781766 http://dx.doi.org/10.3390/toxins12080507 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shim, Jin Seok
Kang, Hyunggoo
Cho, Yongil
Shin, Hyungoo
Lee, Heekyung
Adverse Reactions after Administration of Antivenom in Korea
title Adverse Reactions after Administration of Antivenom in Korea
title_full Adverse Reactions after Administration of Antivenom in Korea
title_fullStr Adverse Reactions after Administration of Antivenom in Korea
title_full_unstemmed Adverse Reactions after Administration of Antivenom in Korea
title_short Adverse Reactions after Administration of Antivenom in Korea
title_sort adverse reactions after administration of antivenom in korea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472312/
https://www.ncbi.nlm.nih.gov/pubmed/32781766
http://dx.doi.org/10.3390/toxins12080507
work_keys_str_mv AT shimjinseok adversereactionsafteradministrationofantivenominkorea
AT kanghyunggoo adversereactionsafteradministrationofantivenominkorea
AT choyongil adversereactionsafteradministrationofantivenominkorea
AT shinhyungoo adversereactionsafteradministrationofantivenominkorea
AT leeheekyung adversereactionsafteradministrationofantivenominkorea